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Background: The environmental contribution of autism spectrum disorder (ASD) is 27 
approximately 17-50%, highlighting the importance of investigating factors potentially 28 
contributing to the likelihood of its development, and of gaining a greater understanding of 29 
the pathogenesis surrounding ASD. The objective of this study was to examine the 30 
association between preeclampsia and ASD using a population-based cohort study. 31 
Methods: All singleton live births in Sweden from 1982-2010 were included, using data 32 
from Swedish National Registers. Exposures of interest included:  1. Preeclampsia (classified 33 
according to ICD-8, ICD-9 and ICD-10) 2. Preeclampsia and small for gestational age (SGA) 34 
combined, used as a proxy for preeclampsia with placental dysfunction. ASD status was 35 
based on ICD-9 and ICD-10. 36 
The cohort consisted of 2,842,230 children, with 54,071 cases of ASD. Follow-up began 37 
from the child’s first birthday and data were censored at first diagnosis of ASD, death, 38 
migration or end of study period (31st December 2016). We conducted multivariate Cox 39 
proportional hazards regression analysis, adjusting for several perinatal and 40 
sociodemographic factors, selected a priori. We further controlled for shared genetic and 41 
familial confounding using sibling-matched analysis. 42 
Results: In the adjusted Cox proportional hazards regression analysis, preeclampsia was 43 
associated with a 25% increase in the likelihood of ASD (Hazard Ratio (HR): 1.25, 95% 44 
CI:1.19, 1.30) compared to those unexposed to preeclampsia, while in the sibling-matched 45 
analysis the HR was 1.17 (95% CI:1.06, 1.28). The HR for preeclampsia and SGA combined  46 
was 1.66 (95% CI:1.49, 1.85) in the adjusted Cox model and 1.95 (95% CI:1.53, 2.48) in the 47 
sibling-matched analysis. 48 
Conclusions: Exposure to preeclampsia or preeclampsia/SGA (i.e. SGA baby exposed to 49 
preeclampsia) was associated with ASD. The stronger association with preeclampsia/SGA 50 
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than preeclampsia alone suggests that placental pathology may be a mechanism for the 51 
increased likelihood of ASD.  52 


























Autism spectrum disorder (ASD) is characterised by persistent impairments in interpersonal 77 
interaction and restricted or repetitive patterns of behaviour (Lai et al., 2014). The prevalence 78 
of ASD is approximately 1.5% (Idring et al., 2015, Lyall et al., 2017), and while genetics 79 
play a major role in the development of ASD, the environmental contribution is estimated to 80 
be between 17-50% (Sandin et al., 2017, Sandin et al., 2014). This highlights the importance 81 
of investigating factors contributing to the likelihood of its onset, and potentially facilitate the 82 
development of appropriate interventions (Jiang et al., 2018). Furthermore, while often 83 
comorbid with intellectual disability, previous results indicate that risk factors for ASD with 84 
and without intellectual disability may differ, and is therefore important to examine ASD 85 
according to the presence or absence of intellectual disability (Langridge et al., 2013, Abel et 86 
al., 2013). 87 
Preeclampsia is one of the leading causes of maternal morbidity and mortality and has 88 
recently been redefined by the International Society for the Study of Hypertension in 89 
Pregnancy (ISSHP) as new-onset hypertension (blood pressure ≥140/90 mmHg on/after 20 90 
weeks’ gestation) accompanied by proteinuria and/or other maternal organ dysfunction and/or 91 
uteroplacental dysfunction (Brown et al., 2018). Preeclampsia is associated with maternal 92 
inflammation, poor placentation and oxidative stress, which may also represent some of the 93 
potential aetiological pathways in the development of ASD (Brown et al., 2014, Yui et al., 94 
2016, Nomura et al., 2017). 95 
While there is conflicting evidence regarding a preeclampsia-ASD relationship, pooled 96 
estimates from epidemiological research suggest preeclampsia is associated with a 50% 97 
increase in odds of ASD (Maher et al., 2018b). However, several limitations of the existing 98 
literature, including residual confounding (for example, family lifestyle factors such as diet), 99 
small sample sizes, and poor phenotyping and use of definitions of hypertensive disorders of 100 
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pregnancy versus preeclampsia, need to be addressed before more definitive conclusions can 101 
be reached.  102 
Therefore, the objective of this study was to examine the association between preeclampsia 103 
and ASD (overall, and stratified by ASD with and without intellectual disability), while 104 
























Study Population  127 
The study population consisted of all singleton live births in Sweden from 1982 to 2010 using 128 
data from the Swedish Medical Birth Register. The Medical Birth Register was linked to the 129 
National Patient Register, Multi-generation Register, Total Population Register and Register 130 
of Education using personal identification numbers (PIN) assigned to each Swedish resident, 131 
in order to conduct the study. 132 
Similar to previous ASD-studies conducted on this population (Sandin et al., 2014, Curran et 133 
al., 2015), follow-up began from the child’s first birthday (or 1st January 1987, when the 134 
ICD-code for ASD became available). Data were censored at first diagnosis of ASD, death, 135 
migration or end of study period (i.e. 31st December 2016). This is in contrast to Sandin et al 136 
(2014) and Curran et al (2015) who included follow-up data until the end of 2009 and 2011 137 
respectively.  138 
Ethical approval was previously obtained from the research ethics committee in Stockholm, 139 
Sweden and informed consent was waived by the ethics committee.  140 
 141 
Exposures 142 
Preeclampsia: Data on preeclampsia was obtained from the Medical Birth Register. The 143 
Medical Birth Register, established in 1973, contains data on over 97% of all births in 144 
Sweden, and includes information on prenatal care, delivery, neonatal care and maternal 145 
socio-demographic and lifestyle factors (The National Board of Health and Welfare 146 
(Socialstyrelsen), 2018). However, since 1982, standardised copies of antenatal, obstetric and 147 
pediatric records were used to collect data, while quality data on obesity and smoking status 148 
during pregnancy also became available, marking the beginning of our study (Ros, 2001).  149 
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A doctor reviews discharge records and notes a diagnosis of preeclampsia at the time of 150 
discharge from the hospital using a standard form, containing the definition of preeclampsia, 151 
accompanied by an ICD-code and checkbox. These are forwarded to the National Board of 152 
Health and Welfare for inclusion in the Birth Register. Preeclampsia is classified according to 153 
the Swedish version of ICD-8 (through 1986), ICD-9 (1987-1996) and ICD-10 (from 1997 154 
onwards) (Ros, 2001).  155 
1. Preeclampsia: ICD-8 [code 637]: Gestational hypertension (blood pressure 156 
≥140/90mmHg on/after 20 weeks’ gestation), accompanied by proteinuria (≥0.3g/day or ≥1 157 
on a urine dipstick) or edema (positive predictive value (PPV)=50%) (Ros, 2001).  158 
ICD-9 [code 642]: Gestational hypertension accompanied by proteinuria (PPV=96%) (Ros, 159 
2001). 160 
ICD-10 [code O14 or O15]: Gestational hypertension accompanied by proteinuria. 161 
2. Preeclampsia with placental dysfunction: We combined preeclampsia and small for 162 
gestational age (SGA) as a proxy for preeclampsia with placental dysfunction, as SGA is 163 
closely associated with uteroplacental dysfunction (Dalman et al., 1999). SGA was classified 164 
according to the Swedish weight-based fetal growth standard (defined as birthweight <2 165 
standard deviations below the mean of the sex-specific and gestational age distributions) 166 
(Khashan et al., 2015). 167 
 168 
Outcome 169 
Data on ASD and intellectual disability were obtained from the National Patient Register. 170 
The National Patient Register contains information on inpatient psychiatric diagnoses from 171 
1973 (obtaining complete national coverage in 1987) (Ludvigsson et al., 2011, Idring et al., 172 
2015). Outpatient data is available in the National Patient Register since 2001 (Idring et al., 173 
2015) (coverage of data from private caregivers is approximately 80%, and public caregivers 174 
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almost 100%) (Ludvigsson et al., 2011). ASD is classified according to ICD-9 [code 299], 175 
available since 1987 and ICD-10 [code F84], available since 1997 (PPV=94.3%) (Curran et 176 
al., 2015). Therefore, index persons (IP) who turned one year of age before 1987 began 177 
follow-up on 1st January 1987, when an ICD-code for ASD first became available.  178 
As risk factors for ASD with/without intellectual disability may differ (Langridge et al., 2013, 179 
Abel et al., 2013), we examined ASD overall, and also stratified results by ASD with 180 
intellectual disability (defined as IQ<70) (Idring et al., 2012, Idring et al., 2015) and ASD 181 
without intellectual disability. For example, if cases of ASD did not receive a diagnosis of 182 
intellectual disability throughout the study period, they were considered to have ASD without 183 
intellectual disability. (Intellectual disability is classified according to ICD-9 [code 317-319] 184 
and ICD-10 [code F70–F79]) (Abel et al., 2013). 185 
 186 
Confounding Variables 187 
Confounders were based on previous literature, and limited to the data available in the 188 
National Registers. They were examined through the use of a directed acyclic graph to gain a 189 
visual representation of the potential confounder pathways (FigureS1). We obtained year of 190 
birth, infant sex, maternal age, maternal and paternal country of birth, birth order, maternal 191 
smoking status, body mass index (BMI) at first antenatal visit, and gestational weight gain 192 
from the Medical Birth Register. Similar to a previous ASD study conducted on this 193 
population (Curran et al., 2015), we also controlled for maternal and paternal depression, 194 
bipolar disorder, and non-affective psychiatric disorders, obtained from the National Patient 195 
Register. Socioeconomic factors including family income and parental level of education 196 
were obtained from the Total Population Register and Register of Education. Information on 197 
all confounders was available for the entire study period with the exception of parental level 198 
of education, available since 1990. (See MethodsS1 for description of confounders). 199 
9 
 
Statistical Analysis 200 
Data were analysed using Stata/MP 14.2. Multivariate Cox proportional hazards regression 201 
analysis was performed to estimate HR and 95% confidence intervals, for preeclampsia; 202 
preeclampsia and SGA (i.e. SGA baby exposed to preeclampsia); and preeclampsia without 203 
SGA, and likelihood of ASD (overall and with/without intellectual disability). The 204 
proportional hazards assumption was assessed graphically and based on Schoenfeld residuals. 205 
Partially adjusted models were stratified by year of birth in order to satisfy the proportional 206 
hazard assumption (model 1). Fully adjusted models (model 2) controlled for year of birth, 207 
infant sex, maternal age, maternal and paternal country of birth, birth order, parental 208 
depression, bipolar disorder and non-affective psychiatric disorders, maternal smoking status, 209 
BMI at first antenatal visit, gestational weight gain, family income and parental level of 210 
education. To account for the possibility of increased diagnosis of ASD in recent years, and 211 
due to a reliance on inpatient psychiatric diagnoses until 2001, we also stratified results by 212 
decade of birth. 213 
Sibling-matched analysis: To control for unmeasured confounding factors shared by siblings, 214 
including family environment, lifestyle factors such as diet, maternal characteristics, and 215 
genetic factors, we conducted a sibling-matched analysis (model 3) using stratified Cox 216 
regression. This method is an extension of the paired binomial model, taking into account 217 
different lengths of follow-up time. The analysis included full and half siblings on the 218 
maternal side consisting of a separate stratum for each family, matched on maternal ID. 219 
While each family has its own baseline probability of ASD, reflecting their shared genetic 220 
and social factors, the exposure groups (i.e. preeclampsia v non-exposure to preeclampsia) 221 
are made within the family, estimating the probability of ASD within the family (Obel et al., 222 
2011). We adjusted for the same potential confounders as model 2 with the exception of 223 
maternal country of birth as this is the same across sibling pairs.  224 
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Post-hoc analysis: We examined the association between SGA-alone and ASD compared to 225 
non-exposure to SGA/preeclampsia. 226 
Sensitivity analyses: As the definition of preeclampsia from 1982-1986 does not correspond 227 
to later years, and the National Patient Register obtained complete national coverage in 1987, 228 
we performed a sensitivity analysis restricting the study population to 1987-2010. In addition, 229 
we excluded births after 2006 to ensure each individual was followed-up for a minimum of 230 
10 years.  231 
Classifying preeclampsia into ‘mild’ or ‘severe’ is not recommended in clinical practice. 232 
However, preeclampsia may present with or without severe features (Brown et al., 2018). As 233 
delivery is the only effective cure for preeclampsia, gestational age is often used as a proxy 234 
for severity. For example, preeclampsia could be considered severe if delivery occurred 235 
before 34 weeks’ gestation (Hernández-Díaz et al., 2009). As a result, sensitivity analyses 236 
were conducted examining the relationship between preeclampsia-ASD (in those born ≥34 237 
weeks’ gestation) and preeclampsia-ASD (in those born <34 weeks’ gestation) compared to 238 
deliveries at ≥34 weeks’ gestation in mothers with no preeclampsia, using the full cohort.  239 
Further sensitivity analyses included ‘preeclampsia without chronic hypertension’ as the 240 
exposure, and ‘preeclampsia with chronic hypertension’ as the exposure. We examined the 241 
association between preeclampsia-ASD excluding those with a family history of mental 242 
illness, while we also included caesarean section in a multivariate model. Furthermore, we 243 
analysed the relationship between preeclampsia with low/intermediate APGAR score at five 244 
minutes. We examined a preeclampsia-ASD relationship by maternal age, in addition to 245 
preeclampsia-ASD by BMI group at time of first antenatal visit. Finally, subgroup analyses 246 
examined a preeclampsia-ASD relationship by gestational age and gender while controlling 247 
for potential confounders. (Gestational age was defined according to ultrasound 248 




Descriptive Statistics  251 
Table 1: There were 2,941,628 live births recorded in the Swedish Medical Birth Register 252 
between 1st January 1982 and 31st December 2010. After exclusions, (figure 1) 2,842,230 253 
children remained in the final cohort. Of these, 1,460,940 (51.4%) were male and 1,381,290 254 
(48.6%) were female. There were 77,600 (2.7%) children exposed to preeclampsia. There 255 
were 54,071 (1.9%) cases of ASD with a median age of diagnosis of 14 years. Of these, 2,024 256 
were exposed to preeclampsia. 257 
 258 
Association between Preeclampsia and ASD  259 
Table 2: In the fully adjusted model (model 2) preeclampsia was associated with a 25% 260 
increase in the likelihood of ASD (HR: 1.25, 95% CI: 1.19, 1.30) compared to those 261 
unexposed to preeclampsia, and this association was reduced in the sibling-matched analysis 262 
(model 3) (HR 1.17, 95% CI: 1.06, 1.28). The HR for preeclampsia and SGA combined was 263 
1.66 (95% CI: 1.49, 1.85) in model 2 and 1.95 (95% CI: 1.53, 2.48) in model 3, and the HR 264 
for preeclampsia without SGA was 1.20 (95% CI: 1.14, 1.26) in model 2 and 1.11 (95% CI: 265 
1.01, 1.23) in model 3.  266 
Preeclampsia and ASD with intellectual disability 267 
Table 2: Preeclampsia was associated with a 56% increase in the likelihood of ASD with 268 
intellectual disability (HR: 1.56, 95% CI: 1.41, 1.73) in model 2 and 32% increase in model 3 269 
(HR: 1.32, 95% CI: 1.07, 1.62). Those exposed to preeclampsia and SGA were nearly 3 times 270 
more likely to have ASD with intellectual disability in model 2 (HR: 2.95, 95% CI: 2.40, 271 
3.64), with similar results observed in model 3 (HR: 3.07, 95% CI: 1.97, 4.79). The HR for 272 
preeclampsia without SGA was 1.40 (95% CI: 1.24, 1.57) in model 2 and 1.15 (95% CI: 0.91, 273 
1.45) in model 3. 274 
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Preeclampsia and ASD without intellectual disability 275 
Table 2: The HR for preeclampsia was 1.19 (95% CI: 1.13, 1.25) in model 2, and 1.13 (95% 276 
CI: 1.01, 1.26) in model 3. Preeclampsia and SGA were associated with a 42% increase in 277 
likelihood of ASD without intellectual disability (HR: 1.42, 95% CI: 1.25, 1.62) in model 2, 278 
and 63% in model 3 (HR: 1.63, 95% CI: 1.22, 2.19). The HR for preeclampsia without SGA 279 
was 1.17 (95% CI: 1.10, 1.23) in model 2, and 1.10 (95% CI: 0.98, 1.23) in model 3. 280 
Stratifying results by decade did not materially change results (Table 3).  281 
Post-Hoc Analysis 282 
The adjusted HR for an SGA only-ASD relationship was 1.60 (95% CI: 1.53, 1.67), while in 283 
the sibling-matched analysis, the HR was 1.82 (95% CI: 1.65, 2.01) (Table 2). 284 
 285 
Sensitivity Analyses 286 
TableS1: When the study population was restricted to 1987-2010, as association between 287 
preeclampsia and ASD was still observed. Similarly, excluding births after 2006 did not 288 
materially change results. Fully adjusted results of the sensitivity analysis suggested that 289 
preeclampsia exposure in those born at ≥34 weeks’ gestational age was associated with an 290 
18% increase in the likelihood of ASD (HR: 1.18, 95% CI: 1.13, 1.24) when compared to 291 
those unexposed to preeclampsia, and born at a similar gestational age. The fully adjusted 292 
result for preeclampsia in those born at <34 weeks’ gestational age (used as a proxy for 293 
preeclampsia with severe features) was 2.04 (95% CI: 1.81, 2.30) when compared to non-294 
exposure to preeclampsia in those born at ≥34 weeks’ gestation. The HR for a preeclampsia-295 
ASD relationship, excluding those with chronic hypertension, was 1.26; and including those 296 
with both preeclampsia and chronic hypertension was a non-significant 0.91. The fully 297 
adjusted HR for preeclampsia (excluding those with family history of mental illness) was 298 
1.28, while including caesarean section in the multivariate model resulted in a HR of 1.21. 299 
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Preeclampsia with a low/intermediate APGAR score at five minutes increased the likelihood 300 
of ASD by 30% compared to non-exposure to preeclampsia and low/intermediate score. 301 
Finally, preeclampsia among mothers <20 years of age and mothers with a BMI of <20 was 302 
associated with the highest odds of ASD (HR: 1.37 and 1.29 respectively) compared to those 303 
of similar maternal age and BMI at first antenatal visit.  (See ResultsS1 and TablesS1 for full 304 
description of results). 305 
 306 
Subgroup Analyses 307 
TableS2: Adjusted subgroup analysis suggested a statistically significant increase in the 308 
likelihood of ASD at all gestational ages when compared to non-exposure to preeclampsia in 309 
those born at ≥37 weeks’ gestation. When adjusted for potential confounders, exposure to 310 
preeclampsia was associated with a 25% increase in the odds of ASD in both male and 311 
















This study aimed to examine the association between preeclampsia and ASD (overall and 326 
with/without intellectual disability) and has yielded two principal findings. First, exposure to 327 
preeclampsia was associated with 25% increased odds of ASD when compared to those 328 
unexposed, after controlling for known potential confounders. The sibling-matched analysis 329 
allowed us to further control for shared genetic and familial factors and reduced the HR to 330 
1.17. However, when results were stratified by ASD with and without intellectual disability, 331 
the HRs were 1.32 and 1.13 respectively. These data are largely in line with a previous 332 
systematic review, which suggested that preeclampsia was associated with a 50% increase in 333 
the odds of ASD, with individual study estimates ranging from 0.90 to 2.36 (Maher et al., 334 
2018b).  335 
Second, as SGA is closely associated with uteroplacental dysfunction (Dalman et al., 1999), 336 
we combined preeclampsia and SGA as a crude proxy for preeclampsia with placental 337 
dysfunction. This decision is also in line with the recent guidelines put forward by ISSHP to 338 
include uteroplacental dysfunction in the definition of preeclampsia (Brown et al., 2018). 339 
Being an SGA baby and exposed to preeclampsia was associated with a 95% increased odds 340 
of ASD when compared to non-exposure to preeclampsia or SGA. This HR increased to 3.07, 341 
when stratified by ASD with intellectual disability, and reduced to 1.63 when stratified by 342 
ASD without intellectual disability (Jones et al., 2017). This observed preeclampsia and SGA 343 
relationship with ASD suggests that impaired placentation may be a common factor 344 
increasing the likelihood of ASD. Furthermore, the post-hoc analysis examining SGA-alone 345 
and ASD further supports this hypothesised mechanism given the modest effect of 346 
preeclampsia on likelihood of ASD compared to that of preeclampsia and SGA combined, or 347 
SGA-alone.  348 
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The precise biological mechanisms contributing to a preeclampsia-ASD relationship are still 349 
unknown however. In a previous study, we demonstrated that exposure of fetal neurons to 350 
maternal serum from term preeclampsia altered fetal cortical neuronal growth and branching 351 
(Curran et al., 2018), while treatment of fetal cortical neurons with conditioned media from 352 
preeclamptic placentae also had similar effects, suggesting secreted factors may be important 353 
(Scott et al., 2018). Such factors may include inflammatory cytokines given that preeclampsia 354 
is associated with chronic immune activation, leading to a significant increase in the 355 
circulation of pro-inflammatory cytokines. Thus, while uncomplicated pregnancies have a 356 
normal systemic inflammatory response (Redman et al., 1999),  preeclampsia results in a 357 
state of exaggerated maternal inflammation (Redman et al., 1999, Maher et al., 2018a). 358 
Therefore, maternal inflammation, a recognised risk factor for poor neurodevelopmental 359 
outcome, could act as a mediator between preeclampsia and development of ASD, and the 360 
pro-inflammatory cytokine interleukin (IL)-6 may be a leading candidate in this regard (Jiang 361 
et al., 2018).  362 
Straughen et al. (2017) demonstrated that placental inflammation of any type is associated 363 
with an increased likelihood of ASD, while circulating levels of maternal IL-6 have been 364 
shown to be inversely associated with brain connectivity and offspring cognition at 12 365 
months of age, as well as short and long-term influences in offspring behaviour in separate 366 
studies (Spann et al., 2018, Rasmussen et al., 2018). This may also partially explain the 367 
increased HR when results were stratified by ASD with intellectual disability, as elevated 368 
mid-gestational levels of numerous cytokines and chemokines such as GM-CSF, IFN-γ, IL-369 
1α, and IL-6 are associated with ASD with intellectual disability, when compared to mothers 370 
of children with either ASD without intellectual disability, developmental delay, or general 371 
population controls (Jones et al., 2017). 372 
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In terms of mediation, while very little data exist in humans, a recent study has shown that 373 
maternal depressive symptoms are associated with higher maternal inflammation, including 374 
IL-6, and this mediated the effect on maternal report of infant negative affect (Gustafsson et 375 
al., 2018), a known risk factor for later adverse neurological outcomes. This may also suggest 376 
that preeclampsia-induced elevations in maternal IL-6 may act as a mediator of the 377 
preeclampsia-ASD association. 378 
Finally, the role of concurrent exposure to antihypertensive medication in the development of 379 
ASD was beyond the scope of this paper, and needs to be explored in future research. This 380 
research question could possibly be addressed using animal models such as the reduced 381 
uterine perfusion pressure (RUPP) model in rats, which mimics many physiological features 382 
of preeclampsia (Walsh et al., 2009), in order to study the impact of antihypertensive 383 
medications administered using clinical relevant treatment protocols, on neurobehavioural 384 
outcomes in offspring.  385 
 386 
Strengths and Limitations 387 
This study had several strengths. It is the largest epidemiological study to investigate the 388 
association between preeclampsia and ASD, with data on over 2.8 million births. Information 389 
on exposure and outcome status was classified according to ICD-coding, obtained from 390 
national registers. Therefore, selection bias and recall bias were not likely an issue. The use 391 
of registry data allowed us to control for a wide range of confounding variables, while 392 
conducting a sibling-matched analysis allowed us to further control, at least in part, for shared 393 
genetic and familial factors.  394 
However, several limitations may also pose a threat to validity of findings. One, each 395 
individual in the present study was followed-up until they reached a minimum of six years of 396 
age (i.e. those born in 2010 followed-up until 2016). While it is possible that not enough time 397 
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had lapsed for a diagnosis of ASD to be received by some individuals, excluding births after 398 
2006 to ensure everyone had at least 10 years of follow-up does not materially change results. 399 
Two, the prevalence of ASD in the current study was 1.9%, compared to previous ASD 400 
studies conducted on this population who had a ~1% prevalence of ASD (Sandin et al., 2014, 401 
Curran et al., 2015). However, we included follow-up data until the end of 2016, whereas 402 
Sandin et al. (2014) and Curran et al. (2015) included follow-up data until the end of 2009 403 
and 2011 respectively. This means that each child in the present study was followed-up for 5-404 
7 additional years compared to the two previous studies. If we restrict our follow-up date to 405 
2011, it results in a more comparable prevalence to that of previous studies (~1%). Given that 406 
children are often not diagnosed with ASD until they are of school age, it is suspected that the 407 
extended follow-up is the reason for the difference in ASD prevalence (Shattuck et al., 2009). 408 
Three, severe cases may have been overrepresented in our data due to a reliance on inpatient 409 
psychiatric diagnoses until 2001 (Ludvigsson et al., 2011). While results of a sensitivity 410 
analysis by decade of birth (Table 3) were not significantly different from our main findings, 411 
the HR of 4.39 for SGA babies exposed to preeclampsia in children with ASD and 412 
intellectual disability born 2000-2010 warrants highlighting, and could possibly reflect an 413 
increased awareness of ASD or increased diagnostic specificity in recent decades. 414 
Four, a lack of robust data on gestational hypertension limited our analysis. Results of 415 
existing studies suggest a non-significant gestational hypertension-ASD relationship (Maher 416 
et al., 2018b). However, if a gestational hypertension-ASD association existed, this would 417 
bias our results towards the null.   418 
Finally, despite controlling for several potential confounders, residual confounding may still 419 
be an issue. While this was reduced in the sibling-matched analysis, this method can only 420 
adjust for factors constant between pregnancies, therefore we cannot rule out the possibility 421 




The apparent preeclampsia/SGA-ASD relationship suggests that placental pathology may be 424 
a common factor increasing the likelihood of ASD. Further research is needed to investigate 425 
the role that maternal inflammation may play, as well as the potential impact of 426 























Key points and relevance 448 
• There is conflicting evidence regarding a preeclampsia-ASD relationship, with several 449 
limitations of the literature being identified 450 
• Adjusted estimates from this population-based cohort study suggest that preeclampsia 451 
is associated with an increase in the likelihood of ASD, while there is a stronger 452 
association between preeclampsia and small for gestational age (SGA) combined (i.e. 453 
SGA baby exposed to preeclampsia) and ASD.  454 
• The stronger association between preeclampsia/SGA combined and ASD suggests 455 
that placental pathology may be a common factor increasing the likelihood of ASD.  456 
• Further research is needed to investigate the role that maternal inflammation may 457 
play, as well as the potential impact of antihypertensive medication in the 458 
development of ASD. 459 
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Table 1: Perinatal and Sociodemographic Characteristics Related to Preeclampsia 
and Autism Spectrum Disorder Among Singleton Live Births in Sweden between 
1982 and 2010  
 No. (%) of Infants  
Characteristic Total Population Preeclampsia 
Total Population 2842230 77600  (2.7) 
ASD 54071  (1.9) 2024  (2.6) 
ASD with intellectual disability 8981 (0.3) 388 (0.5) 
ASD without intellectual disability 45090 (1.6) 1636 (2.1) 
SGA 69355  (2.5) 9761  (12.7) 
First-born child 1210413  (42.6) 49756  (64.1) 
Sex (male)  1460940  (51.4) 40475  (52.2) 
Decade of birth   
1982-1989 773489  (27.2) 19596  (25.3) 
1990-1999 1006338  (35.4) 27635  (35.6) 
2000-2010 1062403  (37.4) 30369  (39.1) 
Maternal age, years   
<20  66946  (2.4) 2393  (3.1) 
20-29 1495876  (52.6) 41463  (53.4) 
30-39 1210467  (42.6) 31217  (40.2) 
≥40 68941  (2.4) 2527  (3.3) 
Gestational age, weeks    
<34  32,332  (1.1) 6375  (8.2) 
34 17,162  (0.6) 2276  (2.9) 
35 29,982  (1.1) 3080  (4.0) 
36 60,016  (2.1) 5155  (6.7) 
37 141036  (5.0) 8583  (11.1) 
38 386963  (13.6) 12516  (16.1) 
39 657765  (23.2) 14653  (18.9) 
26 
 
40 799752  (28.2) 13942  (18.0) 
>40 712440  (25.1) 10894  (14.1) 
5-Minute Apgar score   
0-3 (low) 5530  (0.2) 307  (0.4) 
4-6 (intermediate) 20589  (0.7) 1599  (2.1) 
7-10 (high) 2772613  (99.1) 74412  (97.5) 
Delivery completed by caesarean section 260,650 (9.2) 19,574 (25.2) 
Mother’s country of birth   
Sweden 2272714  (80.0) 64024  (82.5) 
Other Nordic country 85743  (3.0) 2309  (3.0) 
Other country 336123  (11.8) 6602  (8.5) 
Missing 147650  (5.2) 4665  (6.0) 
Father’s country of birth   
Sweden 2244697  (79.0) 63454  (81.2) 
Other Nordic country 76280  (2.7) 2008  (2.6) 
Other country 354182  (12.5) 6909  (8.9) 
Missing 167071  (5.9) 5229  (6.7) 
Maternal depression   
Never 2473216  (87.0) 66912  (86.3) 
Before birth 44440  (1.6) 1355  (1.7) 
After birth 177106  (6.2) 4676  (6.0) 
Missing 147468  (5.2) 4657  (6.0) 
Maternal bipolar disorder   
Never 2669867  (93.9) 72242  (93.1) 
Before birth 3527  (0.1) 115  (0.1) 
After birth 21368  (0.8) 586  (0.8) 
Missing 147468  (5.2) 4657  (6.0) 
Maternal nonaffective disorders   
Never 2674249  (94.1) 72359  (93.2) 
27 
 
Before birth 6898  (0.2) 207  (0.3) 
After birth 13615  (0.5) 377  (0.5) 
Missing 147468  (5.2) 4657  (6.0) 
Paternal depression   
Never 2564110  (90.2) 69636  (89.7) 
Before birth 24621  (0.9) 698  (0.9) 
After birth 106031  (3.7) 2609  (3.4) 
Missing 147468  (5.2) 4657  (6.0) 
Paternal bipolar disorder   
Never 2679318  (94.3) 72562  (93.5) 
Before birth 2661  (0.1) 75  (0.1) 
After birth 12783  (0.4) 306  (0.4) 
Missing 147468  (5.2) 4657  (6.0) 
Paternal nonaffective disorders   
Never 2675845  (94.1) 72458  (93.4) 
Before birth 7155  (0.3) 200  (0.2) 
After birth 11762  (0.4) 285  (0.4) 
Missing 147468  (5.2) 4657  (6.0) 
Smoking at first antenatal visit   
No 2186399  (76.9) 63720  (82.1) 
1-9 cigarettes/day 300389  (10.6) 5886  (7.6) 
≥10 cigarettes/day 165015  (5.8) 2849  (3.7) 
Missing 190427  (6.7) 5145  (6.6) 
BMI at first antenatal visit   
<20 312520  (11.0) 5139  (6.6) 
20-24.9 1200271  (42.2) 27112  (34.9) 
25-29.9 441373  (15.5) 16118  (20.8) 
≥30 167717  (6.0) 10300  (13.3) 
Missing 720349  (25.3) 18931  (24.4) 
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Optimal gestational weight gain by BMI 
group at first antenatal visit 
(Cedergren, 2007) 
  
<20   
Optimum 45641  (1.6) 514  (0.7) 
Inadequate/Excessive 158243  (5.5) 2656  (3.4) 
20-24.9   
Optimum 141430  (5.0) 1958  (2.5) 
Inadequate 2563  (0.1) 43  (0.06) 
Excessive 512433  (18.0) 12424  (16.0) 
25-29.9   
Optimum 36368  (1.3) 803  (1.0) 
Excessive 172818  (6.1) 6,996  (9.0) 
≥30   
Optimum 14994  (0.5) 606  (0.8) 
Excessive 58340  (2.1) 3893  (5.0) 
Missing 1699400  (59.8) 47,707  (61.5) 
Income quintile   
First 513347  (18.1) 11098  (14.3) 
Second 532669  (18.7) 12625  (16.3) 
Third 537973  (18.9) 14611  (18.8) 
Fourth 540823  (19.0) 16657  (21.5) 
Fifth 536843  (18.9) 17281  (22.3) 
Missing 180575  (6.4) 5328  (6.8) 
Parental level of education at IP 
birthyear (available from 1990) 
  
Pre-high school 132,995  (4.7) 3,346  (4.3) 
High school 891,979  (31.4) 26,755  (34.5) 
Post high school 888,712  (31.3) 24,098  (31.0) 
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Missing 928544  (32.7) 23401  (30.2) 
Categories were collapsed if cell count <10, for example, inadequate/excessive weight gain in women 
categorised as BMI<20 were combined for the purpose of displaying data only. 
If missing data >5%, number (%) of missing data reported.  






Table 2: Association between Preeclampsia and Autism Spectrum Disorder With and 
Without Intellectual Disability Among Singleton Live Births in Sweden between 1982 
and 2010  
 Total population Sibling pairs 
 




HR (95% CI)a 
Model 2 
HR (95% CI)b 
Model 3 
HR (95% CI)c 
Preeclampsia 2,024 1.36 (1.31, 1.43) 1.25 (1.19, 1.30) 1.17 (1.06, 1.28) 
Preeclampsia and SGAd 326 1.79 (1.61, 2.00) 1.66 (1.49, 1.85) 1.95 (1.53, 2.48) 
Preeclampsia without SGA 1673 1.32 (1.26, 1.38) 1.20 (1.14, 1.26) 1.11 (1.01, 1.23) 
SGA only 1884 1.77 (1.69, 1.85) 1.60 (1.53, 1.67) 1.82 (1.65, 2.01) 
ASD with intellectual disability (n=8981)  
Preeclampsia 388 1.59 (1.44, 1.76) 1.56 (1.41, 1.73) 1.32 (1.07, 1.62) 
Preeclampsia and SGAd 90 3.11 (2.52, 3.82) 2.95 (2.40, 3.64) 3.07 (1.97, 4.79) 
Preeclampsia without SGA 287 1.42 (1.26, 1.60) 1.40 (1.24, 1.57) 1.15 (0.91, 1.45) 
ASD without intellectual disability (n=45090)  
Preeclampsia 1636 1.32 (1.26, 1.39) 1.19 (1.13, 1.25) 1.13 (1.01, 1.26) 
Preeclampsia and SGAd 236 1.54 (1.36, 1.76) 1.42 (1.25, 1.62) 1.63 (1.22, 2.19) 
Preeclampsia without SGA 1386 1.30 (1.23, 1.37) 1.17 (1.10, 1.23) 1.10 (0.98, 1.23) 
Abbreviations: HR, hazard ratio; 95% CI, 95% confidence interval; SGA, small for gestational age. 
aAdjusted for year of birth. 
bAdjusted for year of birth, infant sex, maternal age, maternal and paternal country of birth, birth order, parental 
depression, bipolar disorder and non-affective psychiatric disorders, maternal smoking status, BMI at first 
antenatal visit, gestational weight gain, family income and parental level of education. 
cAdjusted for same potential confounders as above with the exception of maternal country of birth. 
dReference=no preeclampsia/no SGA. 
Missing data on SGA for 25 cases of ASD (missing data on SGA for 11 cases of ASD with intellectual disability, 
and missing data on SGA for 14 cases of ASD without intellectual disability). 
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Table 3: Association between Preeclampsia and Autism Spectrum Disorder With and Without Intellectual Disability Among Singleton 
Live Births in Sweden by decade  
 Children born 1982-1989 Children born 1990-1999 Children born 2000-2010 
 ASD (n=10938) ASD (n= 24237) ASD (n= 18896) 
 
All ASD (n=54071) 
Exposed cases Model 2 
HR (95% CI)a 
Exposed cases Model 2 




HR (95% CI)a 
Preeclampsia 336 1.15 (1.03, 1.28) 898 1.23 (1.15, 1.32) 790 1.30 (1.21, 1.39) 
Preeclampsia and SGAb 50 1.34 (1.01, 1.77) 124 1.39 (1.16, 1.65) 152 2.14 (1.83, 2.51) 
Preeclampsia without SGA 281 1.14 (1.01, 1.28) 760 1.21 (1.13, 1.31) 632 1.20 (1.11, 1.30) 
ASD with intellectual disability  (n=8981) 
Preeclampsia 60 1.38 (1.07, 1.80) 176 1.53 (1.32, 1.79) 152 1.64 (1.39, 1.94) 
Preeclampsia and SGAb 14 2.57 (1.51, 4.36) 26 1.87 (1.27, 2.76) 50 4.39 (3.31, 5.81) 
Preeclampsia without SGA 44 1.25 (0.92, 1.69) 144 1.52 (1.28, 1.79) 99 1.29 (1.06, 1.58) 
ASD without intellectual disability  (n=45090) 
Preeclampsia 276 1.11 (0.98, 1.25) 722 1.17 (1.09, 1.27) 638 1.23 (1.14, 1.34) 
Preeclampsia and SGAb 36 1.13 (0.81, 1.56) 98 1.30 (1.06, 1.58) 102 1.71 (1.41, 2.08) 
Preeclampsia without SGA 237 1.12 (0.98, 1.28) 616 1.16 (1.07, 1.26) 533 1.18 (1.08, 1.29) 




aAdjusted for year of birth, infant sex, maternal age, maternal and paternal country of birth, birth order, parental depression, bipolar disorder and non-affective psychiatric 
disorders, maternal smoking status, BMI at first antenatal visit, gestational weight gain, family income and parental level of education. 
bReference=no preeclampsia/no SGA 
